Recurrent Squamous Cell Carcinoma of the Hypopharynx Terminated Phase 1 Trials for Sunitinib (DB01268)

IndicationStatusPhase
DBCOND0029504 (Recurrent Squamous Cell Carcinoma of the Hypopharynx)Terminated1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00906360Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and NeckTreatment